TY - JOUR
T1 - Performance of EU-TIRADS in malignancy risk stratification of thyroid nodules
T2 - A meta-analysis
AU - Castellana, Marco
AU - Grani, Giorgio
AU - Radzina, Maija
AU - Guerra, Vito
AU - Giovanella, Luca
AU - Deandrea, Maurilio
AU - Ngu, Rose
AU - Durante, Cosimo
AU - Trimboli, Pierpaolo
N1 - Publisher Copyright:
© 2020 European Society of Endocrinology.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/9
Y1 - 2020/9
N2 - Objective: Several thyroid imaging reporting and data systems (TIRADS) ha ve been proposed to stratify the malignancy risk of thyroid nodule by ultrasound. The TIRADS by the Europea n Thyroid Association, namely EU-TIRADS, was the last one to be published. Design: We conducted a meta-analysis to assess the prevalence of malig nancy in each EU-TIRADS class and the performance of EU-TIRADS class 5 vs 2, 3 and 4 in detecting mal ignant lesions. Methods: Four databases were searched until December 2019. Original art icles reporting the performance of EU-TIRADS and adopting histology as reference standard were inc luded. The number of malignant nodules in each class and the number of nodules classified as true/false positiv e/negative were extracted. A random-effects model was used for pooling data. Results: Seven studies were included, evaluating 5672 thyroid nodules. The prevalence of malignancy in each EU-TIRADS class was 0.5% (95% CI: 0.0-1.3), 5.9% (95% CI: 2.6-9 .2), 21.4% (95% CI: 11.1-31.7), and 76.1% (95% CI: 63.7-88.5). Sensitivity, specificity, PPV, NPV, LR+, LR- A nd DOR of EU-TIRADS class 5 were 83.5% (95% CI: 74.5-89.8), 84.3% (95% CI: 66.2-93.7), 76.1% (95% CI: 63.7-88.5), 85.4% (95 % CI: 79.1-91.8), 4.9 (95% CI: 2.9-8.2), 0.2 (95% CI: 0.1-0.3), and 24.5 (95% CI: 11.7-51.0), respectively. A further improved performance was found after excluding two studies because of limited sample size and low prevalence of ma lignancy in class 5. Conclusions: A limited number of studies generally conducted using a retros pective design was found. Acknowledging this limitation, the performance of EU-TIRADS in stratifying th e risk of thyroid nodules was high. Also, EU-TIRADS class 5 showed moderate evidence of detecting malignant lesions.
AB - Objective: Several thyroid imaging reporting and data systems (TIRADS) ha ve been proposed to stratify the malignancy risk of thyroid nodule by ultrasound. The TIRADS by the Europea n Thyroid Association, namely EU-TIRADS, was the last one to be published. Design: We conducted a meta-analysis to assess the prevalence of malig nancy in each EU-TIRADS class and the performance of EU-TIRADS class 5 vs 2, 3 and 4 in detecting mal ignant lesions. Methods: Four databases were searched until December 2019. Original art icles reporting the performance of EU-TIRADS and adopting histology as reference standard were inc luded. The number of malignant nodules in each class and the number of nodules classified as true/false positiv e/negative were extracted. A random-effects model was used for pooling data. Results: Seven studies were included, evaluating 5672 thyroid nodules. The prevalence of malignancy in each EU-TIRADS class was 0.5% (95% CI: 0.0-1.3), 5.9% (95% CI: 2.6-9 .2), 21.4% (95% CI: 11.1-31.7), and 76.1% (95% CI: 63.7-88.5). Sensitivity, specificity, PPV, NPV, LR+, LR- A nd DOR of EU-TIRADS class 5 were 83.5% (95% CI: 74.5-89.8), 84.3% (95% CI: 66.2-93.7), 76.1% (95% CI: 63.7-88.5), 85.4% (95 % CI: 79.1-91.8), 4.9 (95% CI: 2.9-8.2), 0.2 (95% CI: 0.1-0.3), and 24.5 (95% CI: 11.7-51.0), respectively. A further improved performance was found after excluding two studies because of limited sample size and low prevalence of ma lignancy in class 5. Conclusions: A limited number of studies generally conducted using a retros pective design was found. Acknowledging this limitation, the performance of EU-TIRADS in stratifying th e risk of thyroid nodules was high. Also, EU-TIRADS class 5 showed moderate evidence of detecting malignant lesions.
UR - http://www.scopus.com/inward/record.url?scp=85088846666&partnerID=8YFLogxK
U2 - 10.1530/EJE-20-0204
DO - 10.1530/EJE-20-0204
M3 - Article
C2 - 32544875
AN - SCOPUS:85088846666
SN - 0804-4643
VL - 183
SP - 255
EP - 264
JO - European Journal of Endocrinology
JF - European Journal of Endocrinology
IS - 3
ER -